|We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.|
Soleno (SLNO) is a new formed company through the merger between Capnia and the private Essentials (merger completed in march 2017) thats why its still undiscovered. SLNO has a potential Blockbuster in Phase 3 for the treatment of Prader Willi Syndrome a Rare Disease for which there is no approved treatments . This unknown low float stock which has a terrible low valuation of $24 million could be the next SRPT the stock should be valued way over $100+ million right now for their Phase 3 Program and in the Billion if the outcome of the Phase 3 trial is positive which expected by next year .MYOK and SRPT both rare disease companies hitting Billion Dollar Valuation after Phase 2 results in just 10 patients , you will not find a rare disease company below $100 million valuation with a potential blockbuster in phase 3 that shows how terrible undervalued this stock is .GL
Soleno therapeutics (SLNO)
Market Cap $24 Million
Cash: $8 Million
Shares Out: 47.6 Million ( 36 Million shares held by Insiders & Institutions)
Initiating Coverage June 26, 2017
•Company expects to initiate pivotal Phase III clinical trial by year-end 2017; will take approximately 9-12 months to complete
Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is currently advancing its lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, into a Phase III clinical development program at the end of 2017.
Market Opportunity for PWS is Substantial.
While the lack of approved treatments for PWS alone make it difficult to assess the market, sales of Pfizer’s (NYSE: PFE)
Genotrop in (somatropin) can provide some insight despite being indicate for PWS, in addition to, growth failure due to growth hormone deficiency(GHD),Turner syndrome,idiopathic short stature,and small for gestational age.This product achieved its highest revenue in 2008,with worldwide sales of approximately $900 million.While somatropin has been proven to improve growth and body composition, it does not affect the key disease component of hyperphagia and use is associated with substantial risk. Soleno is developing DCCR for the treatment of PWS,to help address the unmet need of this patient population. To assess the potential of DCCR for PWS, we performed a scenario analysis, which indicates that annual sales could be in the range of $1.1 billion given a moderate price point and 50% market penetrance.
Maxim Group set a $5.00 target price on Capnia, Inc. (NASDAQ:SLNO) in a research note issued to investors on Wednesday, July 5th. The firm currently has a buy rating on the stock.
VERY Strong Insiders & Institutional ownership :
Vivo Ventures LLC 16 012 808
Forward Ventures Services LLC 7 251 728
Technology Partners 7 050 691
Aspire Capital Partners LLC 2 791 666
Ernest Mario, PhD 1 844 328
Oppenheim Asset Management Services SARL 574 853
Medical Strategy GmbH 503 305
Palo Alto Investors LLC 423 738
Sabby Capital LLC 248 067
The Bollard Group LLC 192 217
|© 2020 Knight Sac Media. Data provided by IEX, Alpha Vantage, Coinbase, Binance, Fintel and CityFALCON News|